Kazia Therapeutics Ltd. has licensed a first-in-class SETDB1-targeted epigenetic drug development platform from QIMR Berghofer. The company acquired global rights to the SETDB1 platform, including the lead candidate MSETC, in exchange for an up-front payment and a tiered revenue-sharing structure aligned with development progress.